Watch More Highlights
Sheeba Cantanelli, MPAS, PA-C, of UT Southwestern Simmons Cancer Center, discusses phase III findings that showed metformin, which has been linked to beneficial anticancer effects in some research, did not improve invasive disease–free survival or other outcomes in patients with estrogen or progesterone receptor–positive or –negative breast cancer. The study authors concluded that this agent should not be used as adjuvant treatment (Abstract GS1-08).